review Open AccessTop 1% cited
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Annals of Oncology · 2020 · Vol. 31(11) · pp. 1491–1505
Fernanda Mosele✉(Institut Gustave Roussy)Jordi Remón(HM Hospitales)Joaquı́n Mateo(Vall d'Hebron Hospital Universitari)C. Benedikt Westphalen(LMU Klinikum)Fabrice Barlési(Institut Gustave Roussy)Martijn P. Lolkema(Erasmus MC Cancer Institute)Nicola Normanno(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Aldo Scarpa(University of Verona)Mark E. Robson(Memorial Sloan Kettering Cancer Center)Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center)Nikhil Wagle(Harvard University)Albrecht Stenzinger(Heidelberg University)Jean-François Bonastre(Inserm)Ariane Bayle(Inserm)Stefan Michiels(Inserm)Ivan Bièche(Université Paris Cité)Étienne Rouleau(Institut Gustave Roussy)S. Jezdic(European Society for Medical Oncology)J.-Y. Douillard(European Society for Medical Oncology)J.S. Reis-Filho(Memorial Sloan Kettering Cancer Center)Rodrigo Dienstmann(Vall d'Hebron Institute of Oncology)Fabrice André(Inserm)
Cancer Genomics and DiagnosticsGenetic factors in colorectal cancerPancreatic and Hepatic Oncology ResearchMedicineOncologyInternal medicinePembrolizumabCancerPrecision medicineImmunotherapyPathology
MeSH terms
MaleMedical OncologyCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsPractice Guidelines as TopicPrecision MedicineHigh-Throughput Nucleotide Sequencing
Funding
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- F. Hoffmann-La Roche
- Les Laboratories Pierre Fabre
- Clovis Oncology
- Incyte
- Relay Therapeutics
- Puma Biotechnology
- Astellas Pharma
- European Society for Medical Oncology
- Servier
- Chugai Pharmaceutical
- Foundation Medicine
- NIH Clinical Center
Citations
1,151
FWCI
57.77
field-weighted impact
References
148
Percentile
100%
vs. same field & year
Citations per year
References
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
The Lancet · 2010 · 7,196 citations
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Nature Biotechnology · 2013 · 2,153 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine · 2001 · 11,439 citations
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,350 citations
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
The Lancet Oncology · 2017 · 2,759 citations
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Cancer Cell · 2017 · 2,015 citations
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians · 2018 · 87,314 citations
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Clinical Cancer Research · 2019 · 1,128 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.